

# PANBIO™ COVID-19 TESTS AND EMERGING VARIANTS

No Predicted Impact of the Omicron Variant on Panbio™ COVID-19 Ag Rapid Test Device, Panbio™ COVID-19 Antigen Self-Test, and Panbio™ COVID-19 IgG/IgM Rapid Test Device Based on *In Silico* Analysis<sup>1</sup>

Abbott is continuously monitoring the global SARS-CoV-2 situation through complex processes overseen by the Abbott Pandemic Defense Coalition.<sup>2,3</sup>



**THERE IS NO PREDICTED IMPACT ON PANBIO™ COVID-19 ANTIGEN AND ANTIBODY TEST PERFORMANCE BY ANY OF THESE VARIANTS ANALYZED AS OF NOVEMBER 26, 2021, INCLUDING THE OMICRON VARIANT:**

WHO NOMENCLATURE	LINEAGE	COUNTRY FIRST DETECTED	WHO NOMENCLATURE	LINEAGE	COUNTRY FIRST DETECTED
ALPHA	B.1.1.7	ENGLAND, UK	EPSILON	B.1.427	CALIFORNIA, USA
BETA	B.1.351	SOUTH AFRICA	EPSILON	B.1.429	CALIFORNIA, USA
BETA	B.1.351.2	SOUTH AFRICA	ZETA	P.2	BRAZIL
BETA	B.1.351.3	SOUTH AFRICA	ETA	B.1.525	ENGLAND, UK, NIGERIA
GAMMA	P.1	JAPAN EX MANAUS, BRAZIL	THETA	P.3	PHILIPPINES
GAMMA	P.1.1	BRAZIL	IOTA	B.1.526	NEW YORK, USA
GAMMA	P.1.2	BRAZIL	KAPPA	B.1.617.1	INDIA
DELTA*	B.1.617.2	INDIA	LAMBDA	C.37	PERU
DELTA*	AY.1	INDIA	MU	B.1.621	COLOMBIA
DELTA*	AY.2	INDIA	MU	B.1.621.1	NOT CONFIRMED
DELTA*	AY.3	INDIA	OMICRON	B.1.1.529	MULTIPLE COUNTRIES
DELTA*	AY.3.1	USA	NOT DESIGNATED	A.23.1+E484K	ENGLAND, UK
DELTA*	AY.4	NOT CONFIRMED	NOT DESIGNATED	A.27	NOT CONFIRMED
DELTA*	AY.5	NOT CONFIRMED	NOT DESIGNATED	AT.1	RUSSIA
DELTA*	AY.6	THAILAND	NOT DESIGNATED	AV.1	ENGLAND, UK
DELTA*	AY.7	INDIA	NOT DESIGNATED	B.1.1.318	ENGLAND, UK
DELTA*	AY.8	NOT CONFIRMED			
DELTA*	AY.9	INDIA			
DELTA*	AY.10	NOT CONFIRMED			
DELTA*	AY.11	NOT CONFIRMED			
DELTA*	AY.12	NOT CONFIRMED			



WHO NOMENCLATURE	LINEAGE	COUNTRY FIRST DETECTED
NOT DESIGNATED	B.1.1.519	MEXICO
NOT DESIGNATED	B.1.1.523	NOT CONFIRMED
NOT DESIGNATED	B.1.1.7 WITH E484K	ENGLAND, UK
NOT DESIGNATED	B.1.214.2	NOT CONFIRMED
NOT DESIGNATED	B.1.429.1	NOT CONFIRMED
NOT DESIGNATED	B.1.466.2	INDONESIA
NOT DESIGNATED	B.1.526.1	NEW YORK, USA
NOT DESIGNATED	B.1.526.2	NEW YORK, USA
NOT DESIGNATED	B.1.616	FRANCE

WHO NOMENCLATURE	LINEAGE	COUNTRY FIRST DETECTED
NOT DESIGNATED	B.1.617.3	INDIA
NOT DESIGNATED	B.1.618	INDIA
NOT DESIGNATED	B.1.619	NOT CONFIRMED
NOT DESIGNATED	B.1.620	NOT CONFIRMED
NOT DESIGNATED	B.1.628	NOT CONFIRMED
NOT DESIGNATED	C.1.2	SOUTH AFRICA
NOT DESIGNATED	C.36.3	NOT CONFIRMED
NOT DESIGNATED	C.36.3.1	NOT CONFIRMED
NOT DESIGNATED	R.1	JAPAN AND USA

Abbott will continue to publish evaluations as emerging variants continue to arise.

Product not available in all countries. Available to consumers in select markets. Not all products approved for sale in the U.S.

\* Includes all AY lineages, which as noted by the WHO, is an alias for B.1.617.2 in Pango nomenclature.<sup>4,5</sup>

- <https://www.abbott.com/corpnnewsroom/diagnostics-testing/monitoring-covid-variants-to-ensure-test-effectiveness.html>
- <https://abbott.mediaroom.com/2021-03-11-Abbott-Announces-its-Pandemic-Defense-Coalition-A-Global-Network-of-Expert-Collaborators-Designed-To-Help-Prevent-Future-Pandemics-Currently-Searching-for-COVID-19-Variants>
- <https://www.abbott.com/corpnnewsroom/products-and-innovation/how-we-track-covid-19-variants.html>
- <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/> (Accessed 11/30/2021)
- <http://pango.network/new-ay-lineages/> (Accessed 11/30/2021)

© 2021 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. COL-09037-01 11/21

